WOODLAND HILLS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2118 for the treatment of osteoporosis will be presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR) September 27-30, 2024, in Toronto, ON, Canada. Preclinical and clinical abstracts for AGA2118 were selected by conference organizers as highlights of the meeting.
Details of the presentations are as follows:
Title: AGA2118, a Bispecific Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and Led to Rapid BMD Gains in a First in Human, Single- and Multiple-Dose, Placebo-Controlled Randomized Study
Format: Oral Presentation
Session Date and Time: Friday, Sept 27, 2024, 11:00 – 12:15 pm
Abstract Number: 1011
Title: Long-Term Effects of AGA2118, a Bispecific Antibody that Neutralizes Both Sclerostin and DKK1, on Bone Formation and Bone Resorption Markers in Cynomolgus Monkeys
Format: Poster Session
Session Date and Time: Friday, Sept 27, 2024, 5:30 – 7:30 pm; Saturday, Sept 28, 2024, 2:15 – 3:45 pm
Abstract Number: 109
Title: Preclinical and Clinical Pharmacokinetics of AGA2118, A Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 (DKK1), for the Treatment of Osteoporosis
Format: Poster Session
Session Date and Time: Saturday, Sept 28, 2024, 2:15 – 3:45 pm
Abstract Number: 396
Title: AGA2118, a Bispecific Antibody Neutralizing Both Sclerostin and DKK1, Increased Bone Formation and Decreased Bone Resorption, Leading to a Rapid Increase in Bone Mass and Strength in an Ovariectomized Cynomolgus Monkey Model
Format: Oral Presentation
Session Date and Time: Sunday, Sept 29, 2024, 11:15 – 12:30 pm
Abstract Number: 1071
About Osteoporosis
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis has become a global epidemic, especially for older women, due to an aging population and longer life expectancies. Estimates indicate that more than 200 million patients worldwide suffer from osteoporosis.
Although there are a number of approved therapies for osteoporosis, limitations remain regarding the efficacy and/or safety of each of these options. Research also indicates that most severely osteoporotic individuals do not receive a bone-active agent. As a result, a large unmet medical need remains for the development of new osteoporosis therapies.
About AGA2118
AGA2118 is a Sclerostin x DKK1 bispecific antibody in clinical development for the treatment of osteoporosis. Sclerostin and DKK1 are two critical, negative regulators of WNT signaling in osteoblasts and bone metabolism. By targeting both proteins, AGA2118 is thought to prevent compensatory increase of either agent, aiming to improve magnitude of bone mineral density gains in osteoporotic patients. Angitia wholly owns the bispecific antibody.
About Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team's extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.
Learn more at www.angitiabio.com.
Investor & Media Contact:
William Windham
Solebury Strategic Communications
wwindham@soleburystrat.com
646-378-2946
Forward-Looking Statements
This press release is prepared by Angitia (the “Company”, “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “continue”, “could”, “potential”, “may”, “will”, “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.
These forward-looking statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.
